menu
    • menu
    [{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DB-1303","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DB-1303","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BNT325","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DB-1303","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Duality Biologics

    Menu

    Duality Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT325

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Receive FDA Fast Track for BNT325/DB-1305 Candidate

                            Details : DB-1305 (BNT325) is a next-generation ADC candidate targeting TROP2, evaluated in Phase 1/2 clinical trials for platinum-resistant ovarian epithelial cancer and fallopian tube cancer.

                            Brand Name : DB-1305

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 31, 2024

                            Lead Product(s) : BNT325

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Initiate Pivotal Phase 3 Trial of BNT323/DB-1303 in MBC

                            Details : BNT323 (DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2. It is under phase 3 clinical development for the treatment of metastatic breast cancer.

                            Brand Name : BNT323

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT...

                            Details : BNT323 (DB-1303) is a next-generation Topoisomerase 1 inhibitor, ADC candidate targeting HER2, a cell surface protein. It is under phase 1/2 clinical development for the treatment of HER2-expressing advanced endometrial cancer.

                            Brand Name : BNT323

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 21, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Dr...

                            Details : Under the expanded collaboration, BioNTech will develop, manufacture and commercialize DB-1305, a third generation Trop2 ADC molecule built from DualityBio's proprietary DITAC platform, globally, excluding Mainland China, Hong Kong and Macau Special Admi...

                            Brand Name : DB-1303

                            Molecule Type : Large molecule

                            Upfront Cash : $170.0 million

                            August 07, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy fo...

                            Details : Under the agreement, BeiGene will acquire an exclusive option for a global clinical and commercial license to DB-1312, an investigational, preclinical antibody-drug conjugate therapy for solid tumors and DualityBio will continue preclinical research and ...

                            Brand Name : DB-1312

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand...

                            Details : Under the agreement, new targets will be evaluated with Duality’s linker-payload platform, designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing of antigen low and n...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody...

                            Details : Under the collaboration, BioNTech will gain access to DualityBio’s DB-1303, which is a topoisomerase-1 inhibitor-based ADC directed against HER2, a target that is overexpressed in a variety of cancers. The DB-1303 program received Fast Track designatio...

                            Brand Name : DB-1303

                            Molecule Type : Large molecule

                            Upfront Cash : $170.0 million

                            April 03, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for...

                            Details : DB-1303, a 3rd generation HER2 ADC molecule built from DITAC platform, exhibited potent antitumor activity in both HER2 positive and HER2 low tumor models with superior efficacy, safety and expanded therapeutic window.

                            Brand Name : DB-1303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 20, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

                            Details : Antibody Drug Conjugates (ADC) are a class of highly potent biopharmaceutical drug composed of a targeting antibody linked to a biologically active drug or cytotoxic compound. uPARAP is a novel cancer target overexpressed on the cell surface of mesenchym...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth